# A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients with Obstructive Sleep Apnea (OSA)

> **NCT06103825** · PHASE3 · COMPLETED · sponsor: **Ignis Therapeutics (Suzhou) Limited** · enrollment: 204 (actual)

## Conditions studied

- Sleep Apnea, Obstructive
- Excessive Daytime Sleepiness

## Interventions

- **DRUG:** Solriamfetol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06103825
- **Lead sponsor:** Ignis Therapeutics (Suzhou) Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-01
- **Primary completion:** 2024-07-20
- **Final completion:** 2024-08-19
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2025-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06103825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06103825, "A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients with Obstructive Sleep Apnea (OSA)". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06103825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*